Archive for March 27th, 2009

Osiris Volume Through the Roof, on Bad News (OSIR)

Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock battered this morning on exponential volume.   The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating its Prochymal for Crohn’s disease.  Shares are down 22% at $14.25 and we are over 950 shares as of only 9:57 AM EST. [...]